Prestige BioPharma Balance Sheet Health
Financial Health criteria checks 4/6
Prestige BioPharma has a total shareholder equity of ₩511.5B and total debt of ₩109.4B, which brings its debt-to-equity ratio to 21.4%. Its total assets and total liabilities are ₩702.3B and ₩190.7B respectively.
Key information
21.4%
Debt to equity ratio
₩109.38b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩256.76b |
| Equity | ₩511.55b |
| Total liabilities | ₩190.73b |
| Total assets | ₩702.28b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A950210's short term assets (₩267.0B) exceed its short term liabilities (₩136.1B).
Long Term Liabilities: A950210's short term assets (₩267.0B) exceed its long term liabilities (₩54.6B).
Debt to Equity History and Analysis
Debt Level: A950210 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A950210's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A950210 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A950210 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.8% each year